No cardiovascular benefit with evacetrapib – is this the end of the road for the ‘cetrapibs’?
Sign Up to like & getrecommendations! Published in 2017 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2017.1365838
Abstract: ABSTRACT Introduction: Increasing high-density lipoprotein(HDL) cholesterol levels predict improved cardiovascular outcomes. However, inhibiting cholesteryl ester transfer protein (CETP) to increase HDL cholesterol, with the ‘cetrapibs’ (torcetrapib and dalcetrapib), did not improve cardiovascular clinical outcomes. Despite… read more here.
Keywords: hdl cholesterol; cetrapibs; cardiovascular outcomes; cholesterol ... See more keywords